CBG is a non-intoxicating cannabinoid, meaning it doesn’t produce the “highs” that are synonymous with THC. Because it is present in low levels (usually less than 1%) in most cannabis strains, CBG is considered a minor cannabinoid. Amazingly, however, THC and CBD start out as CBG—it’s the chemical parent of THC and CBD
and CBG is also known to stimulate the alpha-2 receptor. Alpha-2 receptor stimulation has a relaxant effect on muscles and blood vessels. This explains why CBG decreases blood pressure, improves ischemia of the heart, and reduces the intensity of opioid and alcohol withdrawal symptoms. When CBG binds to the alpha-2 receptors in the prefrontal cortex, it helps to improve working memory and executive function. Other benefits of alpha-2 stimulation include treating inflammatory bowel disease and colitis.
Additionally, CBG blocks the 5HT1A receptor while stimulating the TRPV1 and TRPV2 receptors. Blocking the 5HT1A receptor has been shown to improve learning and memory in rodents. As a result, CBG is now being studied as a novel treatment for Alzheimer’s disease. Activation of the TRPV1 receptor, which is also seen in capsaicin, makes CBG a viable option for reducing pain. Activation of the TRPV2 receptor can reduce pain, but it also regulates glucose levels (the goal of diabetic management), improves heart cell function, reduces seizure activity, and helps our cells fight and destroy bacteria. On that same coin, CBG blocks the TRPV8 receptor. Therefore, similar to menthol, it decreases sensitivity to cold and reduces cold-induced inflammation.
A few more notes about this cannabinoid, CBG stimulates PPARgamma resulting in a decrease of pulmonary inflammation caused by asthma. CBG also stimulate GPR55, and as a result, there is a reduction in inflammatory pain and neuropathic pain. Furthermore, there is improvement in bone strength and bone mass. And finally, CBG inhibits keratinocyte proliferation when used to